## ECD Medical Symposium Agenda

Thursday, October 26, 2017 | 7:00 AM to 5:00 PM

### 7:00 – 8:00
**Registration & Continental Breakfast**

### 8:00 – 8:10
**WELCOME ADDRESS**
Mark Heaney, MD, PhD  
Columbia University Medical Center

### 8:10 – 8:40
**GUEST SPEAKER**
Neal Rosen, MD, PhD  
Memorial Sloan Kettering Cancer Center

### 8:40 – 10:10
**BASIC SCIENCE**

<table>
<thead>
<tr>
<th>Oral Presentations</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>1. Adult Patients with Mixed Histiocytosis: Cases from the NIH Clinical Center.</td>
<td>Juviane Estrada-Veras, MD, National Institutes of Health, Bethesda, MD, USA</td>
</tr>
<tr>
<td></td>
<td>2. Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease</td>
<td>Filip Janku, MD, PhD, MD Anderson Cancer Center, Houston, TX, USA</td>
</tr>
<tr>
<td></td>
<td>3. Genomic Analysis Identifies Novel Kinase Alterations in the Histiocytic Neoplasms</td>
<td>Benjamin H. Durham, M.D., Memorial Sloan Kettering Cancer Center, New York, USA</td>
</tr>
<tr>
<td></td>
<td>4. BRAF V600E mutation is associated with a cardiac and neurological phenotype but not mortality in Erdheim-Chester disease: results from a single-center 165-patient cohort</td>
<td>Julien Haroche, MD, PhD, Pitié-Salpêtrière Hospital, Paris, France</td>
</tr>
<tr>
<td></td>
<td>5. 3-D culture of BRAF- and KRAS- mutated Erdheim-Chester disease tissues: Impact of Kinase Inhibitors</td>
<td>Marina Ferrarini, MD, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td>6. BRAF V600E expression in hematopoietic progenitors leads to senescence, myeloid skewing and histiocytosis</td>
<td>Riccardo Biavasco, MD, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy</td>
</tr>
</tbody>
</table>

### 10:10 – 10:30
**Break & Poster Presentations**

### 10:30 – 11:15
**PATHOLOGY**

<table>
<thead>
<tr>
<th>Oral Presentations</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>7. Pro-Collagen Type I Expression In Foamy Histiocytes From Erdheim-Chester Disease Biopsies</td>
<td>Domenico Corradi, MD, University Hospital of Parma, Parma, Italy</td>
</tr>
<tr>
<td></td>
<td>8. A cytologic diagnosis of BRAFV600E Erdheim-Chester disease on pericardial fluid.</td>
<td>P. Chasseur, MD, Erasme Hospital, Anderlecht, Belgium</td>
</tr>
<tr>
<td></td>
<td>9. Increased prevalence of myeloid neoplasms in patients with Erdheim-Chester disease</td>
<td>Gaurav Goyal, MBBS, Mayo Clinic, Rochester, MN, USA</td>
</tr>
</tbody>
</table>

### 11:15 – 12:15
**TREATMENTS**

<table>
<thead>
<tr>
<th>Oral Presentations</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>10. Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Interim Results</td>
<td>Eli L. Diamond, MD, Memorial Sloan Kettering Cancer Center, New York, USA</td>
</tr>
<tr>
<td></td>
<td>11. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis</td>
<td>Ankush Bhatia, MD, Memorial Sloan Kettering Cancer Center, New York, USA</td>
</tr>
<tr>
<td></td>
<td>12. Efficacy of biologics in the treatment of Erdheim-Chester disease</td>
<td>Gaurav Goyal, MBBS, Mayo Clinic, Rochester, MN, USA</td>
</tr>
<tr>
<td></td>
<td>13. Genomics of Erdheim Chester Disease: Implications for Precision Treatment with Targeted Therapy</td>
<td>Aaron M. Goodman, MD, University of California San Diego, La Jolla, CA, USA</td>
</tr>
</tbody>
</table>

### 12:15 – 12:30
**Group Photo of Speakers & Attendees**

### 12:30 – 1:30
**Lunch & Poster Presentations**
ORGAN INVOLVEMENT & IMAGING

14. The Masquerader- ECD presenting as PUO
   Disha Dalela, MBBS, Yale Cancer Biology Institute, New Haven, USA

15. Neurologic Involvement in Erdheim-Chester Disease
   Rahul H. Dave, MD, PhD, National Institutes of Health, Bethesda, MD, USA

16. Abdominal and Thoracic Imaging Presentations of 61 Cases of ECD: Association with BRAFV600E Mutation
   S. Mojdeh Mirmomen and Moozhan Nikpanah, Clinical Center, NIH, Bethesda, MD, USA

17. Renal and Ureteral Involvement in ECD: analysis of a single-centre cohort
   Augusto Vaglio, MD, University Hospital, Parma, Italy

18. Comparative Analysis of Tandem PET/CT & PET/MR Studies in the Evaluation of Patients with Inflammatory Myeloid Neoplasms
   Roei Mazor, MD, Assuta Medical Center, Tel Aviv, Israel

IMPACT: MSKCC targeted tumor sequencing test available for ECD patients
Eli L. Diamond, MD
Memorial Sloan Kettering Cancer Center

POSTER PRESENTATIONS

Title
1. OBSTRUCTIVE UROPATHY AND NEPHROPATHY IN ERDHEIM-CHESTER DISEASE
   Kevin J. O'Brien, RN, MS-CRNP
   National Human Genome Research Institute,
   National Institutes of Health, Bethesda, MD, USA

2. ACUTE NON TRAUMATIC CORTICAL SUBARACHNOID HEMORRHAGE REVEALING ERDHEIM-CHESTER DISEASE (ECD)
   Thomas Papo, MD
   Bichat Hospital Paris-Diderot University
   Paris, France

3. THE SKIN MANIFESTATIONS IN CHINESE PEDIATRIC ERDHEIM-CHESTER DISEASE
   Shan Shi-Jun, MD
   Tianjin Medical University General Hospital, Tianjin, China;
   Ackerman Academy of Dermatopathology, New York, NY, USA

4. CLINICAL AND RADIOLOGICAL RESPONSES TO ORAL METHOTREXATE IN ERDHEIM-CHESTER DISEASE
   Gaurav Goyal, MBBS
   Mayo Clinic, Rochester, MN, USA

5. ERDHEIM-CHESTER DISEASE GLOBAL ALLIANCE STATISTICS & CENTERS OF CARE
   Kathleen Brewer
   ECD Global Alliance, Louisiana, USA